Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Scotts Miracle-Gro

The Best Marijuana Stocks Investors Are Watching The post 2 Marijuana Stocks To Buy Right Now Before 2023? appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Marijuana Stocks To Buy Right Now Before 2023?

This is a stock that rewards long-term investors through continual dividend increases.

Could an Investment in AbbVie Give You $10,000 in Annual Dividend Income by Retirement?

Want $10,000 in Annual Dividend Income by Retirement? Here's How Much You Should Invest in AbbVie Today.

Chevron

Altria

Philip Morris

Verizon

Exxon Mobil

High-dividend ETFs are just about the only diversified funds up this year. And most of them agree on the S&P 500 stocks you need to own.

Top Investors Reveal 7 High-Dividend Stocks You Should Own

NORTH CHICAGO, Ill. , Nov. 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022.

AbbVie to Present at the Evercore ISI HealthCONx Conference

Johnson & Johnson

These businesses may not be "exciting," but that's not such a bad thing right now.

2 Safe Dividend Stocks to Buy Hand Over Fist

While ABBV may outperform JNJ in the next three years, it is helpful to see how Johnson & Johnson's Peers fare on metrics that matter.

This Pharmaceutical Company Is A Better Pick Over Johnson & Johnson Stock

Shares of the pharmaceutical stock have left the S&P 500 index in the dust so far this year.

AbbVie Boosts Its Dividend: Is the Dividend King a Buy?

-        Third approved indication for SKYRIZI ®  (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU) -        A significantly higher proportion of patients on SKYRIZI achieved clinical remission, endoscopic response, mucosal healing and endoscopic remission at week 12 in induction studies compared to placebo 1 , 2 , 3 -        A significantly higher proportion of patients achieved clinical remission and endoscopic response at week 52 with SKYRIZI maintenance 1, 2, 3 -        Crohn's disease is a chronic, systemic inflammatory disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain and can require urgent medical care4, 5 ,6 NORTH CHICAGO, Ill. , Nov. 23, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the European Commission (EC) approved SKYRIZI® (risankizumab, 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) as the first specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.1,2,3  "There are still many patients suffering from debilitating symptoms associated with Crohn's disease, such as abdominal pain and stool frequency, which is why we've embraced the challenge of serving these patients in need," said Thomas Hudson, M.D.

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease

-       Nearly 65 abstracts, including 15 oral presentations on 7 investigational and approved medicines across 8 cancer types, to be presented at the American Society of Hemaotology (ASH) annual congress NORTH CHICAGO, Ill. , Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American Society of Hematology (ASH) annual meeting (December 10-13) in New Orleans, Louisiana.

AbbVie Highlights Blood Cancer Data From Its Growing Oncology Pipeline at the 64th ASH Annual Meeting

The pharmaceutical company's golden goose is about to stop laying golden eggs, but that won't be a permanent problem.

2 Reasons to Buy AbbVie Stock and 1 Reason to Sell

NORTH CHICAGO, Ill. , Nov. 22, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022.

AbbVie to Present at the Piper Sandler Healthcare Conference

The FDA grants priority review status to AbbVie's (ABBV) BLA for epcoritamab for the relapsed/refractory large B-cell lymphoma (LBCL), a form of NHL.

AbbVie (ABBV) BLA for Epcoritamab Gets FDA Priority Tag

Abbott Labs

Target

These stocks offer you a gift: recurrent income just for owning them.

Want Passive Income in 2023? Buy These Dividend Kings

AT&T

This trade increases this position's yield by over 200 basis points while lowering risk for the entire portfolio's dividend stream. With ABBV dealing with rebalancing their portfolio over the next few years, we believe T could be a better store of value for our capital over the next 12-24 months.

Income Portfolio: Why We Sold AbbVie To Buy AT&T

AbbVie is a global biopharmaceutical company with a large portfolio of drugs and therapies. Its most successful drug, Humira, is facing a loss of exclusivity in 2023.

AbbVie: Paid To Wait

The application is supported by data from EPCORE™ NHL-1 Phase 1/2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma, including large B-cell lymphoma If approved for relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy, epcoritamab could become the first subcutaneous bispecific antibody available for the treatment of large B-cell lymphoma NORTH CHICAGO, Ill. , Nov. 21, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Ally Financial

Medtronic

These stocks offer attractive yields now, and investors can look forward to lots of payout raises.

3 Top Dividend Stocks to Buy Now With Yields of 3.4% or More

A RECORD-BREAKING NUMBER OF CONSUMERS PARTICIPATED, WITH BOGO GIFT CARDS SELLING OUT IN JUST A FEW HOURS11 IRVINE, Calif. , Nov. 17, 2022 /PRNewswire/ -- Yesterday, Allergan Aesthetics, an AbbVie company (NYSE:  ABBV ), celebrated the fourth annual – and most successful – BOTOX® Cosmetic Day yet.

Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Most Successful One Yet

Amcor Plc

JPMorgan Chase & Co

Medical Properties Trust

Nutrien

Procter & Gamble

Stellantis N.V. 

Walgreens

A roller-coaster year has sent a lot of deserving names into bargain territory. Here are nine value stocks for investors to consider as we head into 2023.

9 Best Value Stocks to Buy Now

Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.

Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?

AbbVie Inc. (ABBV) Presents at 4th Annual Wolfe Research Healthcare Conference

Amgen

Bristol-Myers

3 pharmaceutical stocks to watch in the stock market right now.

3 Pharmaceutical Stocks For Your November 2022 Watchlist

Intuitive Surgical

Today is a great time to enter these long-term stories.

2 Top Stocks to Buy in November and Hold Forever

Aflac

Coca-Cola

Microsoft

Walmart

With the monetary paradigm shifting beneath our feet, investors have every reason to consider no-brainer dividend stocks to buy for 2023 and beyond. This is no marketing gimmick – folks need to avoid paralysis by analysis and direct their portfolios based on intuitive dynamics.

News for AbbVie Stock (ABBV)